CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 119 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,718,209 | +3.7% | 90,932 | +7.2% | 0.00% | 0.0% |
| Q1 2024 | $3,586,060 | -0.1% | 84,837 | +0.2% | 0.00% | 0.0% |
| Q4 2023 | $3,588,905 | +131.7% | 84,644 | +19.3% | 0.00% | 0.0% |
| Q3 2023 | $1,548,773 | +4.2% | 70,947 | +16.4% | 0.00% | 0.0% |
| Q2 2023 | $1,486,937 | 0.0% | 60,965 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,486,937 | -8.1% | 60,965 | +18.8% | 0.00% | 0.0% |
| Q4 2022 | $1,618,507 | -99.9% | 51,316 | +2.7% | 0.00% | 0.0% |
| Q3 2022 | $1,412,096,000 | -14.1% | 49,968 | -19.7% | 0.00% | 0.0% |
| Q2 2022 | $1,644,436,000 | +38.9% | 62,195 | +83.9% | 0.00% | 0.0% |
| Q1 2022 | $1,184,109,000 | +8.0% | 33,822 | 0.0% | 0.00% | – |
| Q4 2021 | $1,096,509,000 | +11.7% | 33,822 | +1.7% | 0.00% | – |
| Q3 2021 | $981,525,000 | – | 33,272 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |